Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Other Accumulated Expenses: 2012-2024

Historic Other Accumulated Expenses for Ptc Therapeutics (PTCT) over the last 12 years, with Dec 2024 value amounting to $20.6 million.

  • Ptc Therapeutics' Other Accumulated Expenses rose 15.17% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.4 million, marking a year-over-year increase of 15.17%. This contributed to the annual value of $20.6 million for FY2024, which is 92.97% up from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Other Accumulated Expenses is $20.6 million, which was up 92.97% from $10.7 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Other Accumulated Expenses registered a high of $20.6 million during FY2024, and its lowest value of $9.4 million during FY2020.
  • Its 3-year average for Other Accumulated Expenses is $14.4 million, with a median of $12.1 million in 2022.
  • In the last 5 years, Ptc Therapeutics' Other Accumulated Expenses decreased by 21.74% in 2020 and then surged by 92.97% in 2024.
  • Ptc Therapeutics' Other Accumulated Expenses (Yearly) stood at $9.4 million in 2020, then surged by 35.08% to $12.6 million in 2021, then dropped by 4.63% to $12.1 million in 2022, then decreased by 11.45% to $10.7 million in 2023, then skyrocketed by 92.97% to $20.6 million in 2024.